TY - JOUR
T1 - T-type calcium channel blockers as neuroprotective agents
AU - Kopecky, Benjamin J.
AU - Liang, Ruqiang
AU - Bao, Jianxin
N1 - Funding Information:
The project was supported by grants to J.B. from the National Institute of Health (DC010489 and DC011793) and the National Organization for Hearing Research Foundation.
PY - 2014/4
Y1 - 2014/4
N2 - T-type calcium channels are expressed in many diverse tissues, including neuronal, cardiovascular, and endocrine. T-type calcium channels are known to play roles in the development, maintenance, and repair of these tissues but have also been implicated in disease when not properly regulated. Calcium channel blockers have been developed to treat various diseases and their use clinically is widespread due to both their efficacy as well as their safety. Aside from their established clinical applications, recent studies have suggested neuroprotective effects of T-type calcium channel blockers. Many of the current T-type calcium channel blockers could act on other molecular targets besides T-type calcium channels making it uncertain whether their neuroprotective effects are solely due to blocking of T-type calcium channels. In this review, we discuss these drugs as well as newly developed chemical compounds that are designed to be more selective for T-type calcium channels. We review in vitro and in vivo evidence of neuroprotective effects by these T-type calcium channel blockers. We conclude by discussing possible molecular mechanisms underlying the neuroprotective effects by T-type calcium channel blockers.
AB - T-type calcium channels are expressed in many diverse tissues, including neuronal, cardiovascular, and endocrine. T-type calcium channels are known to play roles in the development, maintenance, and repair of these tissues but have also been implicated in disease when not properly regulated. Calcium channel blockers have been developed to treat various diseases and their use clinically is widespread due to both their efficacy as well as their safety. Aside from their established clinical applications, recent studies have suggested neuroprotective effects of T-type calcium channel blockers. Many of the current T-type calcium channel blockers could act on other molecular targets besides T-type calcium channels making it uncertain whether their neuroprotective effects are solely due to blocking of T-type calcium channels. In this review, we discuss these drugs as well as newly developed chemical compounds that are designed to be more selective for T-type calcium channels. We review in vitro and in vivo evidence of neuroprotective effects by these T-type calcium channel blockers. We conclude by discussing possible molecular mechanisms underlying the neuroprotective effects by T-type calcium channel blockers.
KW - CaV3.1
KW - CaV3.2
KW - CaV3.3
KW - Calcium channels
KW - Hearing loss
KW - Neurologic disease
UR - http://www.scopus.com/inward/record.url?scp=84896544423&partnerID=8YFLogxK
U2 - 10.1007/s00424-014-1454-x
DO - 10.1007/s00424-014-1454-x
M3 - Review article
C2 - 24563219
AN - SCOPUS:84896544423
SN - 0031-6768
VL - 466
SP - 757
EP - 765
JO - Pflugers Archiv European Journal of Physiology
JF - Pflugers Archiv European Journal of Physiology
IS - 4
ER -